05 Apr 2009 03:00 AM
Randomized Phase II Trial Of Denosumab In Patients With Bone Metastases From Prostate Cancer, Or Other Neoplasms After Intravenous Bisphosphonates
UroToday.com - N-telopeptide (uNTx) levels measured the in serum of cancer patients reflect bone turnover, excessive bone resorption and are predictive of skeletal related events (SREs), cancer progression and death. The standard of care is the use of bisphosphonates to stabilize the bone environment of these patients. uNTx levels above 50nmol/L/mM creatinine while on bisphosphonate therapy occurs in 20% of patients and correlates with progression of bone lesions and death. In the online edition of the Journal of Clinical Oncology, Dr…
